Core Points - Rosen Law Firm is reminding investors who purchased Ramaco Resources, Inc. securities between July 31, 2025, and October 23, 2025, of the March 31, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3] Case Details - The lawsuit alleges that during the Class Period, Ramaco made materially false and misleading statements regarding its mining activities at the Brook Mine, claiming that significant mining activities had not commenced and that no active work was taking place [5] - As a result of these misstatements, Ramaco is accused of overstating its development progress, leading to misleading positive statements about its business and operations [5] - The lawsuit claims that when the true details were revealed, investors suffered damages [5] Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Compensation - Shareholders who purchased PennyMac securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Financial Performance and Stock Impact - On January 29, 2026, PennyMac reported its fourth quarter and full-year 2025 financial results, revealing a pretax income of $37.3 million for its servicing segment, a significant decrease from $157.4 million in the prior quarter and $87.3 million in Q4 2024 [3]. - The report indicated that pretax income excluding valuation-related items was $47.8 million, down 70% from the previous quarter, primarily due to increased realization of mortgage servicing rights cash flows as lower mortgage rates led to higher prepayment activity [3]. - Following the financial report, PennyMac's stock price dropped by $49.78 per share, or 33.3%, closing at $99.92 per share on January 30, 2026 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - The Class Period for the agilon securities is from February 26, 2025, to August 4, 2025 [1] - Investors who purchased agilon securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3] Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding agilon's financial guidance for 2025, which they knew was unattainable due to industry challenges [5] - It is claimed that defendants overstated the positive financial impact of strategic actions taken by agilon to mitigate risks, leading to materially false statements about the company's business and prospects [5] - The lawsuit asserts that when the true information became public, investors suffered damages [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

Core Viewpoint - Mereo BioPharma Group plc is facing potential legal claims due to alleged violations of federal securities laws related to misleading statements about its Phase 3 clinical trials, which failed to meet primary endpoints [4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating claims against Mereo BioPharma and has set an April 6, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action [2]. - The firm encourages investors who suffered losses in Mereo to contact them directly to discuss their legal options [1][8]. Group 2: Clinical Trial Results - Mereo announced that two Phase 3 studies of setrusumab did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the primary endpoint failures, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. Group 3: Market Reaction - Following the announcement of the failed trials, Mereo's stock price dropped by $2.02 per share, a decline of 87.64%, closing at $0.28 per share on December 29, 2025 [6].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. due to allegations of materially misleading business information issued to the public [1]. Group 1: Legal Action and Investor Rights - Investors who purchased PennyMac securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm is preparing to seek recovery of investor losses [2]. - Interested investors can join the prospective class action by submitting a form or contacting the firm directly [2]. Group 2: Financial Performance and Stock Impact - On January 29, 2026, PennyMac reported its fourth quarter and full-year 2025 financial results, revealing a significant decline in pretax income for its servicing segment, which was $37.3 million, down from $157.4 million in the prior quarter and $87.3 million in Q4 2024 [3]. - The report indicated that pretax income excluding valuation-related items was $47.8 million, reflecting a 70% decrease from the previous quarter, primarily due to increased realization of mortgage servicing rights cash flows as lower mortgage rates led to higher prepayment activity [3]. - Following the financial report, PennyMac's stock price dropped by $49.78 per share, or 33.3%, closing at $99.92 per share on January 30, 2026 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical studies [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma provided investors with optimistic information about the Phase 3 Orbit and COSMIC studies for setrusumab, suggesting it would reduce annualized fracture rates [5]. - It is alleged that while making these positive statements, Mereo BioPharma concealed material adverse facts about the Phase 3 programs, which did not meet their primary endpoints [6]. - The misleading information led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true details were revealed [6]. Group 2: Participation Information - Investors who purchased Mereo ADSs during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7]. - A lead plaintiff must be appointed by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Kyndryl Holdings, Inc. securities, alleging that the company made false and misleading statements regarding its financial condition during the Class Period from August 7, 2024, to February 9, 2026 [1][5]. Summary by Sections Lawsuit Announcement - A class action lawsuit has been filed for Kyndryl Holdings, Inc. securities purchased between August 7, 2024, and February 9, 2026 [1]. - Investors wishing to serve as lead plaintiff must file a motion by April 13, 2026 [1][3]. Compensation Information - Investors who purchased Kyndryl securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4]. Details of the Case - The lawsuit claims that Kyndryl's financial statements were materially misstated, lacked adequate internal controls, and that the company would be unable to timely file its Quarterly Report for the quarter ended December 31, 2025 [5]. - The misleading statements about Kyndryl's business and operations led to investor damages when the true details were revealed [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of New Era Energy & Digital, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Allegations and Impact - New Era Energy & Digital's stock fell 6.9% on December 12, 2025, following a report from short seller Fuzzy Panda Research, which claimed the company spent 2.5 times more on stock promotions than on operating its oil and gas wells [3]. - The report accused CEO E. Will Gray II of a history of mismanagement in penny stock companies over approximately 20 years [3]. Group 2: Legal Actions and Investor Rights - Investors who purchased New Era Energy & Digital securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - BellRing Brands, Inc. is facing a federal securities class action lawsuit due to allegations that the company misrepresented its sales growth and downplayed competitive pressures, leading to significant losses for investors [1]. Summary by Relevant Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased BellRing securities between November 19, 2026, and August 4, 2025, alleging that the company falsely attributed sales growth to increased consumer demand while the actual growth was due to inventory stockpiling by key customers [1]. - The company claimed that it was not experiencing significant competition and had a "competitive moat" in the ready-to-drink category, which was later contradicted by the reality of weakening demand due to competitive pressures [1]. Financial Impact - On May 6, 2025, BellRing disclosed that several key retailers had reduced their inventory levels, which was expected to negatively impact third-quarter growth, leading to a share price drop of approximately 19%, from $78.43 to $63.55 [1]. - Following the release of disappointing fiscal 3Q 2025 results on August 4, 2025, which included a narrowed sales outlook of $2.28-$2.32 billion, the share price fell by about 33%, from $53.64 to $36.18 [1].

Core Insights - Coupang, Inc. experienced a significant drop in share price, falling over 13% due to a report of an additional 165,000 user data being leaked, compounding the previously reported 33 million users affected by a major security breach [1][2] - The interim CEO, Harold Rogers, is under investigation for potential perjury related to statements made about the breach, specifically regarding the involvement of the Korean government in the investigation [2] - A securities class action lawsuit has been initiated, representing investors who acquired Coupang securities between May 7, 2025, and December 16, 2025, due to alleged misleading statements by the company [3][4] Company Developments - The data breach reportedly affected 33.7 million accounts and was executed by a former employee using authentication keys that remained valid post-departure, leading to a $1.2 billion compensation plan and the resignation of the CEO, resulting in a loss of over $8 billion in market value [4] - Following the class period, Coupang filed a report with the SEC indicating that its investigation was conducted under the direction of the government, which raises questions about the accuracy of previous statements made by the company [5] - The firm Hagens Berman is leading the investigation into the claims, focusing on why Coupang's security measures failed to detect the unauthorized access to sensitive customer data [6]